156 related articles for article (PubMed ID: 28455136)
1. In vivo distribution of zoledronic acid in a bisphosphonate-metal complex-based nanoparticle formulation synthesized by a reverse microemulsion method.
Li X; Naguib YW; Cui Z
Int J Pharm; 2017 Jun; 526(1-2):69-76. PubMed ID: 28455136
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic Acid-containing Nanoparticles With Minimum Premature Release Show Enhanced Activity Against Extraskeletal Tumor.
Li X; Valdes SA; Alzhrani RF; Hufnagel S; Hursting SD; Cui Z
ACS Appl Mater Interfaces; 2019 Feb; 11(7):7311-7319. PubMed ID: 30689348
[TBL] [Abstract][Full Text] [Related]
3. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors.
Salzano G; Marra M; Porru M; Zappavigna S; Abbruzzese A; La Rotonda MI; Leonetti C; Caraglia M; De Rosa G
Int J Pharm; 2011 Jan; 403(1-2):292-7. PubMed ID: 21055454
[TBL] [Abstract][Full Text] [Related]
4. Reverse Microemulsion-Based Synthesis of (Bis)phosphonate-Metal Materials with Controllable Physical Properties: An Example Using Zoledronic Acid-Calcium Complexes.
Li X; Naguib YW; Valdes S; Hufnagel S; Cui Z
ACS Appl Mater Interfaces; 2017 Apr; 9(16):14478-14489. PubMed ID: 28252282
[TBL] [Abstract][Full Text] [Related]
5. Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity.
Shmeeda H; Amitay Y; Tzemach D; Gorin J; Gabizon A
J Control Release; 2013 May; 167(3):265-75. PubMed ID: 23419948
[TBL] [Abstract][Full Text] [Related]
6. Development, in vitro and in vivo characterization of zoledronic acid functionalized hydroxyapatite nanoparticle based formulation for treatment of osteoporosis in animal model.
Khajuria DK; Razdan R; Mahapatra DR
Eur J Pharm Sci; 2015 Jan; 66():173-83. PubMed ID: 25444840
[TBL] [Abstract][Full Text] [Related]
7. Novel therapeutic intervention for osteoporosis prepared with strontium hydroxyapatite and zoledronic acid: In vitro and pharmacodynamic evaluation.
Khajuria DK; Vasireddi R; Trebbin M; Karasik D; Razdan R
Mater Sci Eng C Mater Biol Appl; 2017 Feb; 71():698-708. PubMed ID: 27987763
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: a comparative analysis through time lapse video-microscopy technique.
Schiraldi C; Zappavigna S; D' Agostino A; Porto S; Gaito O; Lusa S; Lamberti M; De Rosa M; De Rosa G; Caraglia M
Cancer Biol Ther; 2014; 15(11):1524-32. PubMed ID: 25482949
[TBL] [Abstract][Full Text] [Related]
9. Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic.
Au KM; Satterlee A; Min Y; Tian X; Kim YS; Caster JM; Zhang L; Zhang T; Huang L; Wang AZ
Biomaterials; 2016 Mar; 82():178-93. PubMed ID: 26763733
[TBL] [Abstract][Full Text] [Related]
10. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study.
Marra M; Salzano G; Leonetti C; Porru M; Franco R; Zappavigna S; Liguori G; Botti G; Chieffi P; Lamberti M; Vitale G; Abbruzzese A; La Rotonda MI; De Rosa G; Caraglia M
Biotechnol Adv; 2012; 30(1):302-9. PubMed ID: 21741464
[TBL] [Abstract][Full Text] [Related]
11. Lipid Bilayer-Gated Mesoporous Silica Nanocarriers for Tumor-Targeted Delivery of Zoledronic Acid in Vivo.
Desai D; Zhang J; Sandholm J; Lehtimäki J; Grönroos T; Tuomela J; Rosenholm JM
Mol Pharm; 2017 Sep; 14(9):3218-3227. PubMed ID: 28737925
[TBL] [Abstract][Full Text] [Related]
12. Codelivery of zoledronic acid and doublestranded RNA from core-shell nanoparticles.
Chen L; Ding Y; Wang Y; Liu X; Babu R; Ravis W; Yan W
Int J Nanomedicine; 2013; 8():137-45. PubMed ID: 23319865
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid - a multiplicity of anti-cancer action.
Yuasa T; Kimura S; Ashihara E; Habuchi T; Maekawa T
Curr Med Chem; 2007; 14(20):2126-35. PubMed ID: 17691952
[TBL] [Abstract][Full Text] [Related]
14. Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid.
Porru M; Zappavigna S; Salzano G; Luce A; Stoppacciaro A; Balestrieri ML; Artuso S; Lusa S; De Rosa G; Leonetti C; Caraglia M
Oncotarget; 2014 Nov; 5(21):10446-59. PubMed ID: 25431953
[TBL] [Abstract][Full Text] [Related]
15. Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel.
Ramanlal Chaudhari K; Kumar A; Megraj Khandelwal VK; Ukawala M; Manjappa AS; Mishra AK; Monkkonen J; Ramachandra Murthy RS
J Control Release; 2012 Mar; 158(3):470-8. PubMed ID: 22146683
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid for prevention and treatment of osteoporosis.
Recknor C
Expert Opin Pharmacother; 2011 Apr; 12(5):807-15. PubMed ID: 21385149
[TBL] [Abstract][Full Text] [Related]
17. Bone substitute materials delivering zoledronic acid: physicochemical characterization, drug load, and release properties.
Sörensen TC; Arnoldi J; Procter P; Robioneck B; Steckel H
J Biomater Appl; 2013 Feb; 27(6):727-38. PubMed ID: 22090432
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate remains highly localized after elution from porous implants.
McKenzie K; Dennis Bobyn J; Roberts J; Karabasz D; Tanzer M
Clin Orthop Relat Res; 2011 Feb; 469(2):514-22. PubMed ID: 20809167
[TBL] [Abstract][Full Text] [Related]
19. Oral delivery of zoledronic acid by non-covalent conjugation with lysine-deoxycholic acid: In vitro characterization and in vivo anti-osteoporotic efficacy in ovariectomized rats.
Jeon OC; Seo DH; Kim HS; Byun Y; Park JW
Eur J Pharm Sci; 2016 Jan; 82():1-10. PubMed ID: 26542347
[TBL] [Abstract][Full Text] [Related]
20. Transferrin-Targeted Nanoparticles Containing Zoledronic Acid as a Potential Tool to Inhibit Glioblastoma Growth.
Salzano G; Zappavigna S; Luce A; D'Onofrio N; Balestrieri ML; Grimaldi A; Lusa S; Ingrosso D; Artuso S; Porru M; Leonetti C; Caraglia M; De Rosa G
J Biomed Nanotechnol; 2016 Apr; 12(4):811-30. PubMed ID: 27301207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
